In its second R&D alliance this week, Eli Lilly has formed a partnership with Genetic Leap, a startup that focuses on applying artificial intelligence to the discovery of RNA-targeted t
Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.
Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob
Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug targ
The US authorities have reported the first-ever case of an H5 strain of avian influenza without a known occupational exposure to sick or infected animals in the country.